Under construction – not a live service
Sign in
Not yet taking people in GermanyNo phase

Reminder App to Guide Bladder Filling During Prostate Radiotherapy

Tests a reminder app that prompts men with prostate cancer to drink water before radiotherapy.

Plain-language title generated from the registry record
Registry title: Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer

Key facts

Where
Flensburg, Hanover, Lübeck, and Schwerin, GermanySee the 4 sites

Where in Germany

  • Malteser Hospital St. FranziskusFlensburg, GermanyNo longer taking part
  • Medical Practice for Radiotherapy and Radiation OncologyHanover, GermanyNo longer taking part
  • Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-HolsteinLübeck, GermanyNo longer taking part
  • Medical School Hamburg, Schwerin CampusSchwerin, GermanyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital Schleswig-Holstein
Trial code
NCT06653751
Record updated
22 June 2025
Original description
The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes <200 ml during the radiotherapy course and to demonstrate that this number is lower than without using an app (historical control group).Read full original descriptionShow less

A REminder App to Optimize Bladder FILLing During Radiotherapy of Patients With Prostate CAncer

The primary goal of this study is to assess the impact of an app that reminds patients irradiated for high-risk prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes <200 ml during the radiotherapy course and to demonstrate that this number is lower than without using an app (historical control group).

Inclusion: Histologically proven high-risk prostate cancer; Indication for definitive normo-fractionated radiotherapy; Possession of a smart phone and the ability to use it; Bladder volume at CT-simulation <200 ml; Male gender; Age ≥18 years; Written informed consent; Capacity of the patient to contract.

Exclusion: Radiotherapy of pelvic lymph nodes; Expected non-compliance.

ClinicalTrials.gov NCT06653751